Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.

Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million

• Capital increase by issuing 3,380,500 new shares at a purchase price of EUR 1.50 per new share
• Placement supported by existing and new shareholders
• Capital raise extends cash runway well into Q3 2026
• Proceeds provide financial runway and flexibility to realize strategic partnership for varoglutamstat in chronic kidney disease

Halle (Saale) / Munich, Germany, October 6, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ("Vivoryon" or the "Company"), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it has completed a private placement of new shares to selected investors (“Offering”) with gross proceeds in the amount of EUR 5.1 million.

Pursuant to the results of the Offering, the Company will issue 3,380,500 new ordinary shares at an offering price of EUR 1.50 per share, amounting to gross proceeds of EUR 5.1 million. The new shares issued pursuant to the Offering represent 12.9 % of Vivoryon’s existing issued share capital and will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights. As a consequence, the Company’s number of shares outstanding will increase to 29,614,337 and the Company’s share capital will increase from EUR 262,338.37 by EUR 33,805.00 to EUR 296,143.37 on completion of the Offering.

The private placement was supported by existing and new shareholders.

“This successful financing demonstrates the trust and confidence of both our longstanding and our new investors in our program and company strategy” said Frank Weber, MD, CEO of Vivoryon. “This is the first time Vivoryon has raised capital for the development of varoglutamstat in chronic kidney disease and it is an important step in moving the project forward including securing a strategic partnership. We are currently in discussions with several pharmaceutical companies, and this additional support provides us with the financial runway and financial flexibility to realize the right collaboration.”